Patient characteristics
. | No. patients . | . | . | |
---|---|---|---|---|
Parameter . | RICE (n = 36) . | ICE historical controls (n = 147) . | P . | |
Age, y | .10 | |||
60 and younger | 28 | 129 | ||
Older than 60 | 8 | 18 | ||
Median (range) | 45 (23-72) | 48 (18-68) | ||
Previous chemotherapy | ||||
CHOP | 16 | 65 | ||
CHOP-like | 2 | 31 | ||
NHL-1521 | 16 | 50 | ||
ABVD | 2 | 0 | ||
Stanford-V | 0 | 1 | ||
Disease status | .35 | |||
Relapsed | 23 | 80 | ||
Primary refractory | 13 | 67 | ||
Karnofsky performance status | .23 | |||
80 or greater | 28 | 97 | ||
Less than 80 | 8 | 50 | ||
LDH level | .45 | |||
Elevated | 18 | 61 | ||
Normal | 18 | 86 | ||
Stage at protocol entry | .38 | |||
I or II | 10 | 31 | ||
III or IV | 26 | 116 | ||
Second-line age-adjusted IPI | .19 | |||
Low/low-intermediate | 19 | 59 | ||
High-intermediate/high | 17 | 88 |
. | No. patients . | . | . | |
---|---|---|---|---|
Parameter . | RICE (n = 36) . | ICE historical controls (n = 147) . | P . | |
Age, y | .10 | |||
60 and younger | 28 | 129 | ||
Older than 60 | 8 | 18 | ||
Median (range) | 45 (23-72) | 48 (18-68) | ||
Previous chemotherapy | ||||
CHOP | 16 | 65 | ||
CHOP-like | 2 | 31 | ||
NHL-1521 | 16 | 50 | ||
ABVD | 2 | 0 | ||
Stanford-V | 0 | 1 | ||
Disease status | .35 | |||
Relapsed | 23 | 80 | ||
Primary refractory | 13 | 67 | ||
Karnofsky performance status | .23 | |||
80 or greater | 28 | 97 | ||
Less than 80 | 8 | 50 | ||
LDH level | .45 | |||
Elevated | 18 | 61 | ||
Normal | 18 | 86 | ||
Stage at protocol entry | .38 | |||
I or II | 10 | 31 | ||
III or IV | 26 | 116 | ||
Second-line age-adjusted IPI | .19 | |||
Low/low-intermediate | 19 | 59 | ||
High-intermediate/high | 17 | 88 |